Press Releases

Mar 01, 2022
Dexcom CGM to be evaluated for performance in the hospital and for the potential of more effective glycemic management and improved patient outcomes in the hospital setting Breakthrough Device Designation from the FDA is a critical milestone for in-patient Dexcom CGM use This designation provides a
Feb 14, 2022
SAN DIEGO --(BUSINESS WIRE)--Feb. 14, 2022-- DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on the company at the following upcoming virtual investor conferences: Brice Bobzien , Vice President, Finance will present on behalf of the company at the SVB Leerink 11
Feb 10, 2022
SAN DIEGO --(BUSINESS WIRE)--Feb. 10, 2022-- DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter and fiscal year ended December 31, 2021 . Fourth Quarter 2021 Financial Highlights: Revenue grew 23% versus the same quarter of the prior year to $698.2 million on
Jan 04, 2022
SAN DIEGO --(BUSINESS WIRE)--Jan. 4, 2022-- DexCom, Inc. (NASDAQ:DXCM) today announced that Kevin Sayer , Chairman, President and Chief Executive Officer, will present an update on the company at the 40 th annual J.P. Morgan Healthcare Conference on January 10, 2022 .
Displaying 11 - 18 of 18